PT - JOURNAL ARTICLE AU - Sheila K Patel AU - Jennifer A Juno AU - Wen Shi Lee AU - Ms. Kathleen M. Wragg AU - P. Mark Hogarth AU - Stephen J Kent AU - Louise M Burrell TI - Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences AID - 10.1101/2020.10.06.20207514 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.06.20207514 4099 - http://medrxiv.org/content/early/2020/10/08/2020.10.06.20207514.short 4100 - http://medrxiv.org/content/early/2020/10/08/2020.10.06.20207514.full AB - COVID-19 causes persistent endothelial inflammation, lung and cardiovascular complications. SARS-CoV-2 utilises the catalytic site of full-length membrane-bound angiotensin converting enzyme 2 (ACE2) for cell entry causing downregulation of tissue ACE2. We reported downregulation of cardiac ACE2 is associated with increased plasma ACE2 activity. In this prospective observational study in recovered COVID-19 patients, we hypothesised that SARS- CoV-2 infection would be associated with shedding of ACE2 from cell membranes and increased plasma ACE2 activity.Methods We measured plasma ACE2 catalytic activity using a validated, sensitive quenched fluorescent substrate-based assay in a cohort of Australians aged ≥18 years (n=66) who had recovered from mild, moderate or severe SARS-CoV-2 infection (positive result by PCR testing) and age and gender matched uninfected controls (n=70). Serial samples were available in 23 recovered SARS-CoV-2 patients.Results Plasma ACE2 activity at a median of 35 days post-infection [interquartile range 30-38 days] was 97-fold higher in recovered SARS-CoV-2 patients compared to controls (5.8 [2-11.3] vs. 0.06 [0.02-2.2] pmol/min/ml, p<0.0001). There was a significant difference in plasma ACE2 activity according to disease severity (p=0.033), with severe COVID-19 associated with higher ACE2 activity compared to mild disease (p=0.027). Men (n=39) who were SARS-CoV-2 positive had higher median plasma ACE2 levels compared to women (n=27) (p<0.0001). We next analysed whether an elevated plasma ACE2 activity level persisted following SARS-CoV-2 infection in subjects with blood samples at 63 [56-65] and 114 [111-125] days post infection. Plasma ACE2 activity remained persistently elevated in almost all subjects, with no significant differences between timepoints in post-hoc comparisons (p>0.05).Discussion This is the first description that plasma ACE2 activity is elevated after COVID-19 infection, and the first with longitudinal data indicating plasma ACE2 activity remains elevated out to a median of 114 days post-infection. Larger studies are now needed to determine if persistent elevated plasma ACE2 activity identifies people at risk of prolonged illness following COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational studyFunding StatementThis study was supported by the Victorian Government (SJK, JAJ), an Australian government Medical Research Future Fund award GNT2002073 (SJK, PMH), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology CE140100036 (SJK), NHMRC program grants APP1149990 (SJK) and APP 1055214 (LMB), project grant GNT1145303 (PMH), Medical Research Future Fund award GNT 1175865 (SKP, LMB). JAJ and SJK are supported by NHMRC fellowships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Melbourne Human Research Ethics Committee (#2056689); all participants provided written informed consent in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on reasonable request